WEGOVY® (SEMAGLUTIDE INJECTION) RECEIVES CONDITIONAL MARKETING AUTHORIZATION FROM HEALTH CANADA AS THE FIRST AND ONLY TREATMENT FOR ADULTS WITH NON-CIRRHOTIC MASH, A SERIOUS LIVER DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.